United States Federal Circuit

ResetAA Font size: Print

AmGen Inc. v. Sandoz Inc., 17-1277

Returning once again after climbing and descending the appellate ladder several times, the court held that the defendant had not forfeited its preemption defense and that the Biologics Price Competition and Innovation Act preempts state law remedies for an applicant's failure to comply with aspects of the Act, and affirming the dismissal of the state law claims.

Appellate Information

  • Argued
  • Submitted
  • Decided
  • Published 2017/12/14




  • United States Federal Circuit


FindLaw Career Center

    Select a Job Title

      Post a Job  |  Careers Home

    View More